SGLT2 Inhibitors in Geographic Atrophy

🩺 Protocol Summary

AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.

Primary Research Facility: Washington University (St Louis, Missouri)

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

Diagnosed with, undergoing evaluation for, or seeking treatment related to Retinal Degeneration?

🔍 Study Population / Focus Area (Source: Protocol Primary Condition)

Aged 50 Years or older?

🔍 Protocol Specified Minimum Age: 50 Years

Able to attend required clinic visits at Washington University (St Louis, Missouri)?

🔍 Logistical Requirement: Site at Washington University

📍 Primary Site Map

Site: Washington University — St Louis, Missouri

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.